Clinical Trial Update: Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating apatinib plus sintilimab in advanced gastric cancer that is refractory to at least two prior chemotherapies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Apatinib (apatinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Advanced Metastatic Gastric Cancer | Phase 2 | Status: UNKNOWN